Imatinib mesylate and treatment of chronic myeloid leukemia

被引：0
|
作者：
Yamada, Hisashi [1 ]
机构：
[1] Jikei Univ, Sch Med, Inst DNA Med, Minato Ku, Tokyo 1058461, Japan
来源：
JOURNAL OF PHARMACOLOGICAL SCIENCES | 2008年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：39P / 39P
页数：1
相关论文
共 50 条
  • [31] Hematologic and cytogenetic response to imatinib mesylate in chronic myeloid leukemia
    Narayanan, G.
    Chacko, D. J.
    Koshy, A. A.
    Soman, L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S18 - S18
  • [32] Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
    Alves, Alexandra Rodrigues
    Lima, William Gustavo
    Nagai, Michelly Martins
    Vilela Rodrigues, Joao Paulo
    Ayres, Lorena Rocha
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 52 (04) : 581 - 589
  • [33] Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
    Jacob, L. Abraham
    Bapsy, P. P.
    Babu, K. Govind
    Lokanatha
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2007, 28 (01) : 20 - 25
  • [34] Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate
    LeMarbre, G.
    Schinstock, C.
    Hoyer, R.
    Krook, J.
    Tefferi, A.
    LEUKEMIA RESEARCH, 2007, 31 (03) : 414 - 415
  • [35] Pharmacogenetic Markers of Treatment Response of Imatinib Mesylate in Chronic Myeloid Leukemia Brazilian Patients
    Vieira, Natlia M.
    Leite, Renata
    Reginato, Fabiola
    Zandona, Marilia
    Costa, Tito Vanelli
    Fogliatto, Laura
    Linden, Rafael
    Antunes, Marina Venzon
    Capron, Arnaud
    Wallemacq, Pierre
    Wagner, Sandrine
    Mattevi, Vanessa
    Capra, Marcelo
    BLOOD, 2016, 128 (22)
  • [36] Cytogenetic clonal evolution in chronic myeloid leukemia during imatinib mesylate treatment.
    Klamova, H
    Brezinova, J
    Michalova, K
    Zemanova, Z
    Trneny, M
    BLOOD, 2005, 106 (11) : 291B - 291B
  • [37] Development of a test to predict resistance to imatinib mesylate in the treatment of chronic myeloid leukemia.
    Schultheis, B
    Fidanis, E
    Mahon, FX
    Apperley, JF
    Goldman, JM
    Melo, JV
    BLOOD, 2003, 102 (11) : 71A - 72A
  • [38] Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia
    Nekoohesh, Ladan
    Rostami, Shahrbano
    Nikbakht, Mohsen
    Mohammadi, Saeed
    Babakhani, Davood
    Alimoghaddam, Kamran
    Ghahremani, Mohammad H.
    Chahardouli, Bahram
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01): : E1 - E10
  • [39] Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes
    Stagno, Fabio
    Stella, Stefania
    Spitaleri, Antonio
    Pennisi, Maria Stella
    Di Raimondo, Francesco
    Vigneri, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (03) : 273 - 278
  • [40] Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate
    Garipidou, V
    Vakalopoulou, S
    Tziomalos, K
    ONCOLOGIST, 2005, 10 (06): : 457 - 458
12345